Accurate prediction of drug-drug interactions (DDIs) remains a cornerstone in the development of safe and effective therapeutics. Traditional in vitro models, particularly hepatocyte monocultures, often fall short in reliably forecasting the induction of drug-metabolizing enzymes and transporters beyond CYP3A, such as CYP2C isoforms, UDP-glucuronosyltransferases (UGTs), and P-glycoprotein (P-gp). This limitation poses challenges in assessing the clinical risk associated with new chemical entities, especially when complex interactions like simultaneous induction and inhibition occur.

This webinar introduces the TruVivo®, an all-human 2D+ Hepatic System – a novel in vitro system comprising hepatocytes, stromal, and epithelial feeder cells. We will explore how TruVivo® addresses the shortcomings of traditional models by providing consistent and well-defined induction responses across multiple enzymes and transporters. 

Key discussion points include:

• Validation of TruVivo® for predicting induction of CYP2C8, CYP2C9, CYP2C19, UGT1A4, CYP3A4, and P-gp.
• Application of TruVivo® in delineating complex DDIs involving co-inducers and inhibitors.
• Case studies demonstrating the platform's utility in in situ DDI experiments using clinically relevant drug concentrations.

Guest Speaker: Diane Ramsden, PhD, Senior Director DMPK and Toxicology at Korro Bio

View On-Demand Webinar: Advancing Drug-Drug Interaction Predictions: Utilizing TruVivo®, an All-Human 2D+ Hepatic System